Your browser doesn't support javascript.
loading
The role of miR-223 in breast cancer; an integrated analysis.
Sahin, Yunus; Altan, Zekiye; Karabulut, Aydin; Saadat, Khandakar A S M; Arslan, Ahmet.
Afiliação
  • Sahin Y; Department of Medical Biology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
  • Altan Z; Department of Medical Biology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
  • Karabulut A; Department of Immunology, Institute of Health Sciences, Health Sciences University, Mekteb-i Tibbiye-i Sahane (Hamidiye) Kulliyesi, Uskudar, Istanbul, Turkey.
  • Saadat KASM; Department of Medical Biology, Faculty of Medicine, Institute of Health Sciences, Gaziantep University, Gaziantep, Turkey.
  • Arslan A; Department of Medical Genetics, Faculty of Medicine, Research and Application Hospital, Tekirdag Namik Kemal University, Suleymanpasa, Tekirdag, Turkey. ahmetarslan@nku.edu.tr.
Mol Biol Rep ; 50(12): 10179-10188, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37924447
BACKGROUND: Breast cancer (BRCA) is the most common and leading cause of cancer-related death in women. MicroRNAs (miRNAs) are short non-coding RNA fragments that play a role in regulating gene expression including the cancer-related pathways. Although dysregulation of miR-223 has been demonstrated in recent studies to have prognostic value in various cancers, its diagnostic and prognostic role in BRCA remains unknown. METHODS: The expression and the prognostic value of miR-223 were evaluated using the TCGA data and verified by qRT-PCR. Subsequently, potential oncogenic targets of miR-223 were identified by using three different miRNA target prediction tools and the GEPIA database. In addition to these databases, protein-protein interaction network, molecular functions, prognostic value, and the expression level of miR-223 targets were included by using several other bioinformatics tools and databases; such as, UALCAN, GeneMANIA and Metascape. RESULTS: The bioinformatic results demonstrated that miR-223 downregulated in BRCA and associated with poor prognosis of patients. In vitro experiments validated that miR-223 significantly downregulated in BRCA cells, MCF-7, SK-BR3, MDA-MB-231 and HCC1500, compared to normal breast cell line hTERT-HME1. Furthermore, ANLN, DYNLT1, LRRC59, SLC12A8 and TPM3 genes were identified as the potential oncogenic target genes of miR-223 based on their expression and prognosis in BRCA. Additionally, protein-protein interaction network of these target genes was mainly enriched in dynein intermediate chain binding, cell division, regulation of cell cycle process, and positive regulation of cellular component biogenesis. CONCLUSIONS: The results suggests that miR-223 and its targets, ANLN, DYNLT1, LRRC59, SLC12A8 and TPM3, might be reliable potential prognostic biomarkers in BRCA patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / MicroRNAs Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / MicroRNAs Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article